内蒙古医科大学学报
內矇古醫科大學學報
내몽고의과대학학보
Journal of Inner Mongolia Medical University
2014年
5期
398-402
,共5页
宝莹娜%林宇%祁真%孙晓革%郁圣陶%刘秀兰%索志敏%郁志龙
寶瑩娜%林宇%祁真%孫曉革%鬱聖陶%劉秀蘭%索誌敏%鬱誌龍
보형나%림우%기진%손효혁%욱골도%류수란%색지민%욱지룡
食管鳞癌%后程加速超分割三维适形放射治疗%同步化疗%疗效%毒副作用
食管鱗癌%後程加速超分割三維適形放射治療%同步化療%療效%毒副作用
식관린암%후정가속초분할삼유괄형방사치료%동보화료%료효%독부작용
esophageal squamous cell carcinoma%accelerated hyper-fractionation%radiation therapy%chemotherapy%curative effect%side effect
目的:探讨后程加速超分割三维适形放疗同步化疗治疗食管鳞癌病人的疗效和毒副作用。方法:通过随机分组前瞻性临床研究的方法将我科收治的68例食管鳞癌病人分为对照组和试验组,对照组为36例病人,采用单纯后程加速超分割三维适形放疗( Late-course accelerated hyperfractionated three-dimensional conformal radiotherapy,LCAHCRT),先采用常规分割,剂量达40 Gy时,改为后程加速超分割放疗,每次1.5 Gy,2次/d,间隔大于6 h,总剂量达到60-70 Gy/30~35次。试验组为32例病人,采用上述放疗方法的同时,同步加用化疗顺铂联合氟尿嘧啶。结果:两组有效率分别为试验组96.9%(31/32),对照组75%(27/36)(P<0.05)。1、2、3、4a局部控制率试验组为87.5%、78.1%、61.5%和50%,对照组69.4%、50%、30%和22.7%(P<0.05)。1、2、3、4 a生存率试验组为84.4%、71.9%、53.8%和38.9%,对照组为66.7%、44.4%、26.7%和18.2%(P<0.05)。毒副作用主要为放射性食管炎、食欲减退和骨髓抑制。试验组的放射性食管炎发生率明显高于对照组(P<0.05)。结论:对于食管鳞癌病人,后程加速超分割放疗联合同期化疗与单纯后程加速超分割放疗相比,可以提高肿瘤局控率,改善生存期,尽管毒副作用相比较重,但病人耐受性较好。因此,对于一般状况较好的食管鳞癌病人应该推荐使用后程加速超分割放疗联合同期化疗的方法。
目的:探討後程加速超分割三維適形放療同步化療治療食管鱗癌病人的療效和毒副作用。方法:通過隨機分組前瞻性臨床研究的方法將我科收治的68例食管鱗癌病人分為對照組和試驗組,對照組為36例病人,採用單純後程加速超分割三維適形放療( Late-course accelerated hyperfractionated three-dimensional conformal radiotherapy,LCAHCRT),先採用常規分割,劑量達40 Gy時,改為後程加速超分割放療,每次1.5 Gy,2次/d,間隔大于6 h,總劑量達到60-70 Gy/30~35次。試驗組為32例病人,採用上述放療方法的同時,同步加用化療順鉑聯閤氟尿嘧啶。結果:兩組有效率分彆為試驗組96.9%(31/32),對照組75%(27/36)(P<0.05)。1、2、3、4a跼部控製率試驗組為87.5%、78.1%、61.5%和50%,對照組69.4%、50%、30%和22.7%(P<0.05)。1、2、3、4 a生存率試驗組為84.4%、71.9%、53.8%和38.9%,對照組為66.7%、44.4%、26.7%和18.2%(P<0.05)。毒副作用主要為放射性食管炎、食欲減退和骨髓抑製。試驗組的放射性食管炎髮生率明顯高于對照組(P<0.05)。結論:對于食管鱗癌病人,後程加速超分割放療聯閤同期化療與單純後程加速超分割放療相比,可以提高腫瘤跼控率,改善生存期,儘管毒副作用相比較重,但病人耐受性較好。因此,對于一般狀況較好的食管鱗癌病人應該推薦使用後程加速超分割放療聯閤同期化療的方法。
목적:탐토후정가속초분할삼유괄형방료동보화료치료식관린암병인적료효화독부작용。방법:통과수궤분조전첨성림상연구적방법장아과수치적68례식관린암병인분위대조조화시험조,대조조위36례병인,채용단순후정가속초분할삼유괄형방료( Late-course accelerated hyperfractionated three-dimensional conformal radiotherapy,LCAHCRT),선채용상규분할,제량체40 Gy시,개위후정가속초분할방료,매차1.5 Gy,2차/d,간격대우6 h,총제량체도60-70 Gy/30~35차。시험조위32례병인,채용상술방료방법적동시,동보가용화료순박연합불뇨밀정。결과:량조유효솔분별위시험조96.9%(31/32),대조조75%(27/36)(P<0.05)。1、2、3、4a국부공제솔시험조위87.5%、78.1%、61.5%화50%,대조조69.4%、50%、30%화22.7%(P<0.05)。1、2、3、4 a생존솔시험조위84.4%、71.9%、53.8%화38.9%,대조조위66.7%、44.4%、26.7%화18.2%(P<0.05)。독부작용주요위방사성식관염、식욕감퇴화골수억제。시험조적방사성식관염발생솔명현고우대조조(P<0.05)。결론:대우식관린암병인,후정가속초분할방료연합동기화료여단순후정가속초분할방료상비,가이제고종류국공솔,개선생존기,진관독부작용상비교중,단병인내수성교호。인차,대우일반상황교호적식관린암병인응해추천사용후정가속초분할방료연합동기화료적방법。
Objective:To investigate the curative effect and toxicity of late-course accelerated hyper-fractionated three-dimensional conformal radiotherapy and chemotherapy in the treatment of patients with esophageal squamous cell carcinoma in Inner Mongolia. Methods:By the method of randomized prospective clinical study,68 patients with esophageal squamous cell carcinoma from Inner Mongolia were divided into control group and experimental group. The control group included 36 cases,treated by late-course accelerated hyper-fractionated three-dimensional conformal radiotherapy( Late-course accelerated hyper-fractionated three-dimensional conformal radiotherapy,LCAHCRT). At the dose of 40Gy,they received late-course accelerated hyper-fractionation radiotherapy,1. 5 Gy each time,2 times a day,more than 6 hour intervals,total dose 60-70Gy/30-35. At the same time of the ra-diotherapy, the test group containing 32 cases, received synchronous chemotherapy. Chemotherapy regimen wasDDP and 5-FU 500 mg. Results:The efficiency rate of the test group was 96. 9%(31/32),and the rate of the control group was 75%(27/36). (P<0. 05). 1,2,3,4-year local control rate of the test group were 87 . 5%, 78 . 1%, 61 . 5% and 50%. 1 , 2 , 3 , 4-year local control rate of the control group were 69 . 4%,50%,30% and 22 . 7%( P<0 . 05 ) . 1 ,2 ,3 ,4-year survival rate of the test group were 84 . 4%,71 . 9%,53 . 8%and 38 . 9%. And the rate of control group were 66 . 7%,44 . 4%, 26. 7% and 18. 2% (P<0. 05). The main side effects were radioactive esophagitis,loss of appetite, fatigue and bone marrow suppression. The side effects of the test group were higher than that of the control group ( P<0. 05 ). Conclusion:The results demonstrate, for the patients with esophageal squamous cell carcinoma of the Inner Mongolia nationality,radiotherapy and synchronous chemotherapy compared with radiotherapy alone,the curative effect is better than the latter,toxic and side effects of concurrent chemoradiotherapy group are serious,and are well tolerated in the patients. Therefore,for the general good of patients with esophageal squamous cell carcinoma,radiotherapy and synchronous chem-otherapy should be recommend, especially late course accelerated hyper-fractionation radiotherapy method.